Phase 4 N=80 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients
Pre-eclampsia Aggravated
Primary: TOF 0.9 Achieving Time — 1.6; 2.1 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=409 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Arthritis, Psoriatic
Primary: American College of Rheumatology 20 (ACR20) Response at Week 12 — 24.3; 58.0; 51.9 percentage of participants — p=<0.001
Phase 2 N=36 Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration
Rheumatoid Arthritis
Primary: Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX — 118.14; 122.63; 116.71 ng*hr/mL/mg
Phase 3 N=176 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Reversal of Coagulopathy
Primary: Percentage of Participants Achieving Hemostatic Efficacy During Surgery — 89.7; 75.3 percentage of participants
Phase 1 N=24 Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: AUC (Hour*ng/mL) Single Dose Pharmacokinetics of Brisdelle™ (Paroxetine Mesylate) Capsules 7.5 mg — 86.95; 78.80; 38.90 Hour*ng/mL
Phase 2 N=41 Linezolid to Treat Extensively-Drug Resistant Tuberculosis
Pulmonary Tuberculosis · Multidrug Resistant Tuberculosis · Extensively Drug Resistant Tuberculosis
Primary: Number of Patients Converted to Sputum Culture Negative in Each Arm, With Data Censored at 4 Months. — 15; 7 participants
Phase 1 N=10 Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
Type 2 Diabetes Mellitus
Primary: Recovery Time From Hypoglycemia to Euglycemia — 74.49; 88.90; 109.81 Minutes
Phase 2 N=100 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
N/A N=585 Study of the Molecular Genetics of Menstrual Migraine
Migraine
Primary: Progesterone Receptor Gene Polymorphism PROGINS in Women With Menstrual Migraine and Women Without Migraine — 208; 112; 64; 39 participants — p=0.513
Phase 2 N=34 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease…
Phase 3 N=40 Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients
Herpes Simplex
Primary: Number of Participants With a Herpes Simplex Virus (HSV) Infection — 0; 0 Participants
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
Phase 3 N=202 PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Assisted Reproductive Techniques · Reproductive Technology, Assisted
Primary: Total Number of Oocytes Retrieved — 10.9; 9.7 oocytes
Phase 3 N=2,832 ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly
Aging · Healthy
Primary: Changes in Cognitive Abilities of Memory From Baseline to Year 10 — -10.6; -11.2; -12.7; -9.4 units on a scale — p=0.43
Phase 2 N=34 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start — 23.3 percentage of participants